Industry News
Biotechnology Industry News
Seaport Therapeutics and Hemab…
Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets.
Boehringer Ingelheim and Amgen…
Boehringer Ingelheim and Amgen have both canned early-stage immunology candidates after the prospects showed little clinical promise.
The second time is not the charm…
The second time is not the charm for Replimune’s melanoma candidate RP1. After spurning the immunotherapy last July, the FDA has now rejected the biotech’s resubmitted application.
Oricell Therapeutics has now…
Oricell Therapeutics has now raised over $110 million in its final funding round before the Chinese CAR-T therapy biotech seeks to go public.
When Fierce last caught up with…
When Fierce last caught up with GSK’s head of oncology R&D back in November, we were told to “stay tuned” for the pharma to publish its own hotly anticipated data on a pair of antibody-drug
The Orano group has selected a new…
The Orano group has selected a new leader for its oncology-focused Orano Med subsidiary in Frederic Desdouits, who has sat on the governance board of the company since 2022. Desdouits’ appointment was attributed to his
Many gene therapy outfits focus on…
Many gene therapy outfits focus on technical advances, Ocugen CEO Shankar Musunuri, Ph.D., said, meaning they miss out on broader commercial success.
Bioprocessing is evolving rapidly…
Bioprocessing is evolving rapidly in a shifting landscape of innovative and complex products, processes and technologies. In this new era, three important trends are materializing—and there’s a critical (but perhaps unsung) enabler to thank for
Gilead has tucked another drug…
Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise its option on Kymera Therapeutics’ preclinical anticancer molecular glue degrader.
Avalyn Pharma is eyeing an IPO as…
Avalyn Pharma is eyeing an IPO as the biotech seeks more funds to take its inhaled versions of approved drugs for lung conditions into phase 3 trials.
NAMs are no longer theoretical….
NAMs are no longer theoretical. The real challenge now is choosing the right tools—and generating data that holds up when it counts.
Join global leaders at ASGH 2026…
Join global leaders at ASGH 2026 to bridge the gap between lab breakthroughs and market execution while unlocking growth in Asia’s health economy.
Roche has joined Big Pharma peers…
Roche has joined Big Pharma peers in the emerging degrader-antibody conjugate space, paying C4 Therapeutics $20 million upfront and committing more than $1 billion in milestones to partner on two oncology targets.
Jeito Capital has hailed the $1.2…
Jeito Capital has hailed the $1.2 billion it has secured as the “largest raise ever achieved” by an independent biopharma-focused European fund.
After entering 2026 hungry for…
After entering 2026 hungry for deals, Gilead Sciences has wasted no time eating its fill.
Following a research collaboration…
Following a research collaboration established in 2021, Astellas Pharma has reached an agreement to license a Dyno Therapeutics gene therapy vehicle—an adeno-associated virus (AAV) capsid engineered for therapeutic delivery to skeletal muscle.
Three years after its…
Three years after its OrbiMed-backed series A in 2023, Sidewinder Therapeutics is adding to its nest egg courtesy of a clutch of new investors. The San Diego startup has sunk its teeth into a $137
Eli Lilly has handed AC Immune 10…
Eli Lilly has handed AC Immune 10 million Swiss francs ($12.5 million) to expand their Alzheimer’s disease collaboration as a candidate moves closer to the clinic.
Sanofi’s TSLP and IL-13…
Sanofi’s TSLP and IL-13 inhibitor has aced a pair of mid-stage studies for respiratory diseases, but missed on a phase 2 eczema trial.
The agreement allows Biogen to…
The agreement allows Biogen to apply the platform to advance antisense therapeutics against multiple undisclosed targets. Alloy will receive an upfront payment and is eligible for milestone payments and tiered royalties on any resulting products.